CervoMed (CRVO) Operating Income (2010 - 2026)
CervoMed (CRVO) posted Operating Income of -$8.1 million for Q1 2026, up 2.65% sequentially from -$8.3 million in Q4 2025, and down 52.95% YoY from -$17.2 million in Q1 2025.
CervoMed (CRVO) Operating Income (2010 - 2026) Analysis & Trends
CervoMed has reported Operating Income for 17 years, with the latest figure at -$8.1 million in Q1 2026.
- Quarterly Operating Income fell 52.95% year-over-year to -$8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$31.1 million (down 48.57% YoY) and the FY2025 annual result came in at -$28.3 million, down 55.23% from the prior year.
- Operating Income improved to -$8.1 million in Q1 2026 per CRVO's latest filing, from -$8.3 million in the prior quarter.
- Over five years, Operating Income peaked at -$904054.0 in Q3 2022 and troughed at -$8.3 million in Q4 2025.
- A 5-year average of -$4.3 million and a median of -$4.2 million in 2022 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2023: Operating Income jumped 92.88% in 2022, then plunged 195.9% in 2023.
- Over 5 years, Operating Income stood at -$938823.0 in 2022, then sank by 164.21% to -$2.5 million in 2023, then tumbled by 191.92% to -$7.2 million in 2024, then retreated by 15.06% to -$8.3 million in 2025, then increased by 2.65% to -$8.1 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$8.1 million, -$8.3 million, and -$8.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | CervoMed | 26.64 Mn | 26.64 Mn | - | -6.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.68 Mn |
| Mar 31, 2026 | -8.11 Mn |
| Dec 31, 2025 | -8.33 Mn |
| Sep 30, 2025 | -8.04 Mn |
| Jun 30, 2025 | -6.62 Mn |
| Mar 31, 2025 | -5.30 Mn |
| Dec 31, 2024 | -7.24 Mn |
| Sep 30, 2024 | -5.40 Mn |
| Jun 30, 2024 | -3.00 Mn |
| Mar 31, 2024 | -2.59 Mn |
| Dec 31, 2023 | -2.48 Mn |
| Sep 30, 2023 | -2.68 Mn |
| Jun 30, 2023 | -1.23 Mn |
| Mar 31, 2023 | -1.43 Mn |
| Dec 31, 2022 | -938,823.00 |
| Sep 30, 2022 | -904,054.00 |
| Jun 30, 2022 | -4.25 Mn |
| Mar 31, 2022 | -4.55 Mn |
| Dec 31, 2021 | -3.47 Mn |
| Sep 30, 2021 | -12.69 Mn |